Genmab AS is a biotechnology business based in the US. Genmab AS shares (GMAB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $20.45 – a decrease of 3.45% over the previous week. Genmab AS employs 2,635 staff and has a trailing 12-month revenue of around $19.8 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $20.45 |
|---|---|
| 52-week range | $20.50 - $32.88 |
| 50-day moving average | $23.81 |
| 200-day moving average | $27.06 |
| Wall St. target price | $37.56 |
| PE ratio | 20.1863 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $1.02 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $20.5 from 2024-11-19
| 1 week (2024-11-13) | -5.36% |
|---|---|
| 1 month (2024-10-18) | -10.79% |
| 3 months (2024-08-20) | -24.60% |
| 6 months (2024-05-20) | -30.95% |
| 1 year (2023-11-20) | -36.85% |
|---|---|
| 2 years (2022-11-18) | -52.93% |
| 3 years (2021-11-19) | 41.47 |
| 5 years (2019-11-20) | 22.26 |
Valuing Genmab AS stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genmab AS's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Genmab AS's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Genmab AS shares trade at around 20x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Genmab AS's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7133. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Genmab AS's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Genmab AS's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $6.9 billion.
The EBITDA is a measure of a Genmab AS's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $19.8 billion |
|---|---|
| Operating margin TTM | 38.25% |
| Gross profit TTM | $14.6 billion |
| Return on assets TTM | 10.95% |
| Return on equity TTM | 14.92% |
| Profit margin | 23.7% |
| Book value | $502.60 |
| Market Capitalization | $13.7 billion |
TTM: trailing 12 months
We're not expecting Genmab AS to pay a dividend over the next 12 months.
Genmab AS's shares were split on a 5:1 basis on 30 April 2018 . So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Genmab AS shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Genmab AS shares which in turn could have impacted Genmab AS's share price.
Over the last 12 months, Genmab AS's shares have ranged in value from as little as $20.5 up to $32.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genmab AS's is 0.859. This would suggest that Genmab AS's shares are less volatile than average (for this exchange).
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.